Cargando…
Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings
BACKGROUND: Annual mortality from neonatal sepsis is an estimated 430 000–680 000 infants globally, most of which occur in low- and middle-income countries (LMICs). The WHO currently recommends a narrow-spectrum β-lactam (e.g. ampicillin) and gentamicin as first-line empirical therapy. However, avai...
Autores principales: | Darlow, Christopher A, McEntee, Laura, Johnson, Adam, Farrington, Nicola, Unsworth, Jennifer, Jimenez-Valverde, Ana, Jagota, Bhavana, Kolamunnage-Dona, Ruwanthi, Da Costa, Renata M A, Ellis, Sally, Franceschi, François, Sharland, Mike, Neely, Michael, Piddock, Laura, Das, Shampa, Hope, William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704437/ https://www.ncbi.nlm.nih.gov/pubmed/36177766 http://dx.doi.org/10.1093/jac/dkac323 |
Ejemplares similares
-
Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance
por: Darlow, Christopher A., et al.
Publicado: (2022) -
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2021) -
Correction to: Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2022) -
Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria
por: Darlow, Christopher A., et al.
Publicado: (2021) -
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales—authors’ response
por: Darlow, Christopher A, et al.
Publicado: (2022)